The European Medicines Agency (EMA) has launched a new version of its corporate website - www.ema.europa.eu
The website has a number of new features to improve user experience, including:
- an improved search, allowing users to find content easily and to filter their search results. EMA plans to further refine this functionality in the future;
- a ‘responsive’ design for cleaner display on mobile devices;
- simpler URLs based on the location and title of webpages or documents;
- an updated visual design offering users a clearer reading experience and simpler navigation.
The website’s content and structure remain unchanged. Although the site’s URLs are new, URLs from the previous website will continue to work for every page and document, thanks to one-to-one redirects. Although these redirects will be available for an indefinite period, EMA encourages users who have bookmarked any URLs to consider updating them at their convenience now that the new site is live.
The new website has been designed to work optimally on the latest web browsers. EMA carried out the project to relaunch the website in collaboration with the European Commission’s Directorate General for Informatics (DIGIT). DIGIT will also host and maintain the new website on behalf of EMA.
To provide general feedback on the new EMA's corporate website or to make suggestions for future improvement, please write to firstname.lastname@example.org. EMA will take all feedback and suggestions into account, but will not be able to reply to individual email messages.
The European Medicines Agency has published the following reflection papers for consultation:
- Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health – Deadline 21 December 2018
- Reflection paper on resistance in ectoparasites – Deadline 31 August 2019
For more information on the European regulatory system for medicines, please consult our brochure.
The European Medicines Agency has released for public consultation the following draft consultations concerning herbal medicines:
- Draft guideline on specifications: test procedures and acceptance criteria for herbal substances, herbal preparations and herbal medicinal products/traditional herbal medicinal products - Revision 3
- Draft guideline on quality of herbal medicinal products/traditional herbal medicinal products - Revision 3
The first addresses specifications, i.e. those tests, procedures, and acceptance criteria used to assure the quality of the herbal substances/preparations and herbal medicinal products at release and during the shelf-life, while the second one covers the general quality aspects of herbal medicinal products for human and veterinary use, including traditional herbal medicinal products for human use.
Please note that EMA may collect and further process some personal data of stakeholders and interested parties who submit contributions to the consultations. For more information, see Specific privacy statement for public consultations.
For more information on the European regulatory system for medicines, please click here (brochure available in all languages).
We are pleased to send you our latest edition of the monthly Newsletter which includes decisions by our Scientific Committees and updates on medicines safety. We hope that you will find this useful and welcome any feedback.